264 related articles for article (PubMed ID: 23280565)
1. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
[TBL] [Abstract][Full Text] [Related]
2. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
[TBL] [Abstract][Full Text] [Related]
3. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
[TBL] [Abstract][Full Text] [Related]
4. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
[TBL] [Abstract][Full Text] [Related]
5. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
Siejka A; Schally AV; Block NL; Barabutis N
BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
[TBL] [Abstract][Full Text] [Related]
7. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
Siejka A; Schally AV; Block NL; Barabutis N
Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
[TBL] [Abstract][Full Text] [Related]
8. The effect of LHRH antagonist cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells.
Siejka A; Schally AV; Barabutis N
Horm Metab Res; 2014 Jan; 46(1):21-6. PubMed ID: 23839655
[TBL] [Abstract][Full Text] [Related]
9. Hormonal manipulation of benign prostatic hyperplasia.
Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
[TBL] [Abstract][Full Text] [Related]
10. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
[TBL] [Abstract][Full Text] [Related]
11. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
[TBL] [Abstract][Full Text] [Related]
13. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
14. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis.
Popovics P; Cai R; Sha W; Rick FG; Schally AV
Prostate; 2018 Sep; 78(13):970-980. PubMed ID: 29786867
[TBL] [Abstract][Full Text] [Related]
16. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
[TBL] [Abstract][Full Text] [Related]
18. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
